Inventor
CLAUDIA WAGNER
Inventor
DE
Overview
Patents· 16 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%
C07KPeptides24%
A61KPreparations for medical, dental or toiletry purposes23%
C12NMicroorganisms or enzymes18%
G01NInvestigating or analysing materials by determining their chemical or physical properties8%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms2%
G16BBioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology2%
PatentTitleYear
12,570,760Antigen binding proteins specifically binding PRAME202612,297,252T cell receptors with improved pairing202512,295,996Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers202512,295,994Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers202512,295,995Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers202512,269,881Antigen binding proteins specifically binding MAGE-A202512,214,025Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers202512,209,137Antigen binding proteins specifically binding CT45202512,188,932Method for high throughput peptide-MHC affinity screening for TCR ligands202512,011,459Methods for manufacturing T cells by direct sorting and compositions thereof202411,998,607T cell receptors and immune therapy using the same202411,932,689Engineered T cell receptors and immune therapy using the same202411,859,009Antigen binding proteins specifically binding PRAME202411,840,577Antigen binding proteins specifically binding MAGE-A202311,324,812Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers202211,236,145T cell receptors and immune therapy using the same against PRAME positive cancers2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2026Patents assigned to IMMATICS BIOTECHNOLOGIES GMBH (16)· patent assignee history
2022–2026Based in DE· patent location history
2024Patents assigned to IMMATICS US INC (1)· patent assignee history
2025Patents assigned to Emmatics Biotechmiogieg GmbH (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| IMMATICS BIOTECHNOLOGIES GMBH | 16 | 2022–2026 |
| Emmatics Biotechmiogieg GmbH | 1 | 2025 |
| IMMATICS US INC | 1 | 2024 |
Locations
| Location | Patents | Span |
|---|---|---|
| DE | 16 | 2022–2026 |